6onv: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "6onv" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
The entry | ==Crystal structure of HIV-1 LM/HT Clade A/E CRF01 gp120 core in complex with (S)-MCG-III-027-D05.== | ||
<StructureSection load='6onv' size='340' side='right'caption='[[6onv]], [[Resolution|resolution]] 3.25Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6onv]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6ONV OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ONV FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EPE:4-(2-HYDROXYETHYL)-1-PIPERAZINE+ETHANESULFONIC+ACID'>EPE</scene>, <scene name='pdbligand=MWA:(3S)-N-(4-chloro-3-fluorophenyl)-1-(methylsulfonyl)piperidine-3-carboxamide'>MWA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6onv FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6onv OCA], [http://pdbe.org/6onv PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6onv RCSB], [http://www.ebi.ac.uk/pdbsum/6onv PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6onv ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The HIV-1 envelope glycoprotein (Env) trimer mediates virus entry into cells. The "closed" conformation of Env is resistant to non-neutralizing antibodies (nnAbs). These antibodies mostly recognize occluded epitopes that can be exposed upon binding of CD4 or small-molecule CD4 mimetics (CD4mc). Here, we describe a new family of small molecules that expose Env to nnAbs and sensitize infected cells to antibody-dependent cellular cytotoxicity (ADCC). These compounds have limited capacity to inhibit virus infection directly, but are able to sensitize viral particles to neutralization by otherwise non-neutralizing antibodies. Structural analysis shows that some analogs of this family of CD4mc engage the gp120 Phe43 cavity by contacting the highly-conserved D368 residue, making them attractive scaffolds for drug development.IMPORTANCE HIV-1 has evolved multiple strategies to avoid humoral responses. One efficient mechanism is to keep its envelope glycoproteins (Env) in its "closed" conformation. Here we report on a new family of small molecules able to "open-up" Env, thus exposing vulnerable epitopes. This new family of molecules bind in the Phe43 cavity and contact the highly-conserved D368 residue. The structural and biological attributes of this family of molecules make them good candidates for drug development. | |||
A new family of small-molecule CD4-mimetic compounds contact the highly conserved aspartic acid 368 of HIV-1 gp120 and mediates ADCC.,Ding S, Grenier MC, Tolbert WD, Vezina D, Sherburn R, Richard J, Prevost J, Chapleau JP, Gendron-Lepage G, Medjahed H, Abrams C, Sodroski J, Pazgier M, Smith AB 3rd, Finzi A J Virol. 2019 Sep 25. pii: JVI.01325-19. doi: 10.1128/JVI.01325-19. PMID:31554684<ref>PMID:31554684</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6onv" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Pazgier, M]] | [[Category: Pazgier, M]] | ||
[[Category: Sherburn, R]] | [[Category: Sherburn, R]] | ||
[[Category: Tolbert, W D]] | |||
[[Category: Clade a/e cf01]] | |||
[[Category: Hiv-1 gp120]] | |||
[[Category: Viral protein]] | |||
[[Category: Viral protein-inhibitor complex]] | |||
